Category - Developments

Canopy Growth (TSX:WEED; NYSE: CGC) inked an investment financing, and partnership and a supply agreement with 48North Cannabis (TSXV:NRTH). Under the supply accord, 48North would supply Canopy with dried cannabis...

Canopy Growth (TSX:WEED; NYSE:CGC) has entered an 18-month strategic supply agreement with a unit of MediPharm Labs (TSXV:LABS) to purchase up to 900 kg of cannabis extract. Canopy Growth has committed to purchase a...

Health Canada approved Opsens’ (TSX:OPS; OTCQX:OPSSF) diastolic pressure ratio (dPR) proprietary resting index, which measures intracoronary pressure and establishes a diagnosis with the heart at rest to guide treatment...

Canopy Growth (TSX:WEED; NYSE: CGC) has completed four product transfers of legal cannabis to Ohio-based Battelle, the world’s largest non-profit research and development organization, to support medical research...

Leerink initiated coverage of 10 biopharma and generic stocks, saying the sector is rich with companies developing drugs with the aim to treat and/or definitively cure conditions ranging from rare, severe inherited...

Following a successful pre-IND meeting with FDA, closely-held Interface Biologics (IBI) is preparing to initiate a Phase 2 trial with its dexamethasone intravitreal implantin patients with diabetic macular edema. The...

Canopy Growth (TSX:WEED; NYSE:CGC) completed the acquisition of the assets of ebbu, a leader in hemp research and innovation, for $25-million and 6,221,210 common shares. Under the accord, Canopy would pay up to an...

Closely-held Lobo Genetics entered into a non-binding letter of intent with Cassowary Capital (TSXV:BIRD) that will result in a reverse takeover of Cassowary by Lobo. Cassowary is a capital pool company on the TSX...

Canopy Rivers’ (TSXV:RIV) portfolio company, Radicle Medical Marijuana, received a production and sales licence from Health Canada to supply and sell finished cannabis products for both the medical and adult-use market...

Analysts for Canaccord Genuity, Echelon Wealth Partners and A.G.P./Alliance Global Partners are raising the prospects of Profound Medical’s (OTCQX:PRFMF; TSX:PRN) TULSA-PRO device as a treatment for benign prostatic...